CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Significant Decrease in Short Interest

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 5,655 shares, a decrease of 81.2% from the July 15th total of 30,057 shares. Based on an average daily volume of 329,145 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

CytoMed Therapeutics Trading Up 4.5%

GDTC stock traded up $0.04 during mid-day trading on Thursday, reaching $0.84. 27,840 shares of the company traded hands, compared to its average volume of 267,739. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17. CytoMed Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $3.68. The firm’s 50 day moving average price is $0.99 and its 200 day moving average price is $1.01.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.